We work with collaborators around the world and are committed to partnerships that create value for our investors.

Hanmi Pharmaceutical Co., Ltd.

Athenex received exclusive rights to Hanmi Pharmaceutical’s Orascovery platform which is based on the encequidar technology. Under the terms of the agreement, Athenex has the rights to the development and commercialization of all products derived from the Orascovery program for all indications worldwide, except for Korea.

Hanmi Pharmaceutical Co., Ltd., headquartered in Seoul, South Korea, was established in 1973 and has more than 200 products on the market.

Learn more

Eli Lilly and Company

Athenex entered into a collaboration and supply agreement with Eli Lilly and Company to conduct a Phase 1b study to evaluate the safety and tolerability of Athenex’s oral paclitaxel and encequidar in combination with Eli Lilly and Company’s CYRAMZA® (ramucirumab), a vascular endothelial growth factor (VEGF) Receptor 2 antagonist, in patients with advanced gastric and esophageal cancer. This collaborative study is currently underway.

Learn more


Athenex and PharmaEssentia executed a license agreement granting PharmaEssentia rights to tirbanibulin ointment, formerly known as KX2-391, and KX2-361 for certain dermatological conditions; PharmaEssentia also sub-licensed the rights of oral paclitaxel and encequidar, oral irinotecan and encequidar as well as oral docetaxel and encequidar in Singapore, Taiwan and Vietnam.

Founded in 2003, PharmaEssentia Corporation is headquartered in Taipei, Taiwan. Its mission is to discover, develop and deliver to the market a range of efficacious, safe and cost-effective therapeutic products for human disease through new drug research and development.

Learn more


Athenex and Zenith Technology Corporation, through its affiliate ZenRx, have executed a collaborative licensing agreement granting Zenith Technology commercial rights to oral paclitaxel and encequidar and oral irinotecan and encequidar, in New Zealand and Australia. As part of the collaboration, the first clinical study of oral paclitaxel and encequidar was conducted at Dunedin Hospital in Otago, New Zealand.

Zenith Technology, established in 1987, is an independent contract research organization located in New Zealand.

Learn more


In December 2017, Athenex entered into a strategic partnership with Almirall, S.A. (BME: ALM) to develop and commercialize Athenex’s tirbanibulin ointment, formerly known as KX2-391, in the United States and Europe for the treatment of actinic keratosis.

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM).

Learn more

Xiangxue Pharmaceuticals

Athenex and Xiangxue Pharmaceuticals executed a license agreement granting Xiangxue Pharmaceuticals exclusive rights to KX2-361, for all oncology indications, in greater China and Singapore. In December 2019, Athenex has expanded its strategic partnership with Xiangxue Pharmaceuticals to exclusively develop and commercialize oral paclitaxel and encequidar, oral irinotecan encequidar, as well as tirbanibulin ointment, including for the treatment of actinic keratosis in Mainland China, Hong Kong and Macao.

Xiangxue Pharmaceutical Co., Ltd (XPH) is a publicly traded pharmaceutical company headquartered in Guangzhou, China. The primary business of the company is the manufacturing and marketing of pharmaceutical products, including herbal medicines, western medicines and biomedical engineering products. The company is actively expanding its product pipeline through research and development efforts and through licensing in areas of unmet medical needs.

Learn more

Xiangxue Life Sciences

Xiangxue Life Sciences, a subsidiary of Xiangxue Pharmaceutical, is a Chinese biopharmaceutical company focused on TCR-based therapies for cancer and has developed a new generation TCR-T, named HATac, which consists of the expression of high binding affinity soluble T-cell receptors on the engineered T-cells to target HLA-antigenic peptide complex on certain types of cancer cells.

Athenex and Xiangxue Life Sciences have established a joint venture, Axis Therapeutics Limited, for the research, development and commercialization of T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, based on the novel approach on high-affinity TCR developed by Xiangxue Life Sciences. Axis Therapeutics Limited, owned initially as 55% by Athenex and 45% by Xiangxue Life Sciences, has in-licensed the worldwide (excluding mainland China) rights of all the intellectual properties and know-how of the TCR-T immunotherapy technology from Xiangxue Life Sciences.

Learn more

Hong Kong Polytechnic University & McGill University

Athenex executed an agreement with Hong Kong Polytechnic University and McGill University for an exclusive license to a series of BCRP inhibitors and also the joint development of oral topotecan.
Founded in 1821, McGill University is one of Canada’s best-known institutions of higher learning and one of the leading universities in the world. McGill has the highest percentage of PhD students of any Canadian research university and its alumnae include at least 139 Rhodes Scholars and 12 Nobel Prize winners.

Learn more

logo Hong Kong Polytechnic University

The Hong Kong Polytechnic University is a public university located in Hung Hom, Hong Kong. PolyU has an international faculty and student community and has developed a global network with more than 440 institutions in 47 countries and regions. PolyU offers 220 postgraduate, undergraduate and sub-degree programs for more than 32,000 students every year.

Learn more

Photos of our Partnerships